Sleep Number Corp: Form 10-Q for the period ended Sep 27, 2025
Filed with the SEC on Nov 5, 2025 and accepted by EDGAR at Nov 5, 2025, 16:21 ET.
Management's discussion and analysis
As filed, 44,567 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
OPERATIONS
Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to provide a
reader of the Company’s condensed consolidated financial statements with a narrative from the perspective of
management on its financial condition, results of operations, liquidity and certain other factors that may affect the
Company’s future results. MD&A is presented in seven sections:
- Forward-Looking Statements and Risk Factors
- Business Overview
- Results of Operations
- Liquidity and Capital Resources
- Non-GAAP Data Reconciliations
- Critical Accounting Policies
Forward-looking Statements and Risk Factors
The discussion in this Quarterly Report on Form 10-Q contains certain forward-looking statements that relate to
future plans, events, financial results or performance. You can identify forward-looking statements by those that
are not historical in nature, particularly those that use terminology such as “may,” “will,” “should,” “could,”
“expect,” “anticipate,” “believe,” “estimate,” “plan,” “project,” “predict,” “intend,” “potential,” “continue” or the
negative of these or similar terms. These statements are subject to certain risks and uncertainties that could
cause actual results to differ materially from the Company’s historical experience and its present expectations or
projections. These risks and uncertainties include, among others:
- Changes in economic conditions and consumer sentiment and related impacts on discretionary consumer spending;
- Interest rates remain elevated, and may further increase and impact the cost of servicing the Company’s
indebtedness;
- Ability to remain in compliance with the financial covenants in the credit agreement governing the Company’s credit
facility, which will depend on the Company’s ability to execute its business plans, and if the Company cannot remain in
compliance with such financial covenants, the Company must seek alternative financing options, access to which may
depend on factors beyond the Company’s control or require the Company to accept unfavorable terms;
- Availability of attractive and cost-effective consumer credit options;
- Ability to achieve cost savings, efficiencies and other benefits from its business restructuring actions and to avoid
adverse effects;
- Effectiveness and efficiency of the Company’s marketing strategy and promotions;
- Ability to execute Sleep Number’s Total Retail distribution strategy;
- Ability to compete effectively;
- Ability to achieve and maintain high levels of product and service quality;
- Ability to improve and expand the product line and execute new product introductions;
- Ability to protect the Company’s technology, trademarks and brand, and the adequacy of its intellectual property
rights;
- Dependence on, and ability to maintain working relationships with key suppliers and third parties, including some that
are the only source of supply or services currently used by the Company;
- Fluctuations in commodity costs or third-party delivery or logistics costs and other inflationary pressures;
- Risks inherent in global-sourcing activities, including tariffs, foreign regulation, geo-political turmoil, war, pandemics,
labor challenges, foreign currency fluctuations, inflation, climate or other disasters and resulting supply shortages, and
production and delivery delays and disruptions;
- Operating with minimal levels of inventory, which may leave the Company vulnerable to supply shortages;
- Risks of disruption in the operation of any of the Company’s facilities and operations, including manufacturing,
assembly, distribution, logistics, field services, home delivery, headquarters, product development, retail or customer
service operations;
- Ability to effectively complete potential future acquisitions and business combinations;
17 | 3Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION
- Sleep Number’s ability, and the ability of its suppliers and vendors, to attract, retain and motivate qualified and
effective personnel;
- Ability to comply with existing and changing government regulations and laws, and to commercialize new products
and innovations that meet those existing and changing government regulations and laws;
- Ability to identify and withstand cyber threats that could compromise the security of the Company’s systems or those
of third parties upon which it relies and could result in a data breach or business disruption;
- Risks associated with advancements in or adoption of artificial intelligence technologies;
- Adequacy of the Company’s and third-party information systems, and costs and disruptions related to upgrading or
maintaining these systems;
- Volatility of Sleep Number stock, its removal from various stock indices and the potential negative effects of
shareholder activism or of changes in coverage by securities analysts;
- Unfavorable tax treatment;
- Environmental, social and governance risks, including increasing scrutiny and evolving regulatory and stakeholder
expectations; and
- Ability to adapt to climate change and readiness for legal or regulatory responses thereto.
Additional information concerning these, and other risks and uncertainties is contained under the caption “Risk
Factors” in Part I, Item 1A. in the Company’s Annual Report on Form 10-K and in Part II. Item 1A. in subsequent
Quarterly Reports on Form 10-Q.
The Company has no obligation to publicly update or revise any of the forward-looking statements contained in this
Quarterly Report on Form 10-Q.
Business Overview
Sleep Number is a wellness company and market leader in the design, manufacturing, marketing and distribution of highly
innovative sleep solutions. The Company’s purpose is to improve lives by personalizing sleep; to date, it has improved the
lives of over 16 million people. Sleep Number’s Smart Sleepers benefit from individualized sleep experiences, night after
night, and are experiencing the physical, mental and emotional benefits of life-changing sleep.
Sleep Number’s life-changing, differentiated smart beds combine physical and digital innovations, integrating unparalleled
physical comfort with a highly advanced sleep wellness platform. The smart beds offer the Company’s signature firmness
adjustability, enabling each sleeper adjustable comfort. Embedded digital sensors learn the sleep needs of each
individual; “sense and do” technology uses the sensed data to automatically adjust the smart bed to keep the sleeper
comfortable throughout the night. Active temperature balancing technology supports the ideal climate for each sleeper and
solves a prevalent sleep challenge. Additionally, the smart beds are an exceptional value, with personalized sleep insights
delivered daily, new features regularly added to all smart beds through over-the-air updates and prices to meet most
budgets. Sleep Number® smart beds provide unmatched features, benefits and comfort that can lead to improved sleep
health and wellness for both sleepers.
The Company’s advantaged business model is supported by its consumer innovation strategy: an individualized, digital
sleep wellness platform, a network of millions of highly engaged Smart Sleepers who are loyal brand advocates, a
vertically integrated operating model and a culture of individuality, with an ambitious vision to become one of the world’s
most beloved brands.
The Company’s 3,200 mission-driven team members are focused on driving value creation, including our exclusive direct-
to-consumer selling in 611 stores and online, which meets customers whenever and wherever they choose to provide an
exceptional experience and a lifelong relationship. Additionally, the Company partners with world-leading institutions to
bring the power of 36 billion hours of longitudinal sleep data to sleep science and research.
The bedding industry has been in a sector level recession for three years with mattress industry unit volumes returning to
an estimated 24 million units in 2024, the lowest level since 2015. Consumer sentiment remains well below historical
averages, and high interest rates are putting ongoing pressure on the housing market. Consumers continue to scrutinize
spending, with inflation and other factors weighing on their purchasing power. In November 2025, the Company
introduced its turnaround strategy, a focused, company-wide effort to reposition the brand, expand reach to new customer
groups, and reignite growth. The aim is to drive value for shareholders, customers and team members with efforts rooted
in the consumer through all dimensions of the business.
18 | 3Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION
Results of Operations
Quarterly and Year-to-Date Results
Quarterly and year-to-date operating results may fluctuate significantly as a result of a variety of factors, including
increases or decreases in sales, timing, amount and effectiveness of advertising expenditures, changes in sales return
rates or warranty experience, timing of investments in growth initiatives and infrastructure, timing of store openings/
closings and related expenses, changes in net sales resulting from changes in the Company’s store base, timing of new
product introductions and related expenses, timing of promotional offerings, competitive factors, changes in commodity
costs, disruptions in global supplies or third-party service providers, seasonality of retail and bedding industry sales,
consumer sentiment and general economic conditions. The extent to which these external factors will impact the
Company’s business and its consolidated financial results will depend on future developments, which are highly uncertain
and cannot be predicted. Therefore, the historical results of operations may not be indicative of the results that may be
achieved for any future period.
Highlights
Financial highlights for the three months ended September 27, 2025 were as follows:
- Net sales for the three months ended September 27, 2025 of $343 million decreased 20% from $427 million for the
same period one year ago driven by lower volume and reduced store count.
- The net sales change resulted from a 19% Total Retail comparable sales decrease. For additional details, see the
components of total net sales change on page 21.
- Average sales per store (sales for stores open at least one year, Total Retail, including online, phone and chat) on a
trailing twelve-month basis for the period ended September 27, 2025 totaled $2.3 million, compared with $2.7 million
for the same period one year ago.
- Operating loss for the three months ended September 27, 2025 was $40 million, compared with operating income of
$8 million for the same period one year ago. The $49 million decrease in operating income was driven by the lower
gross profit, partially offset by a $5 million reduction in operating expenses.
- Adjusted EBITDA for the three months ended September 27, 2025 was $13 million, compared to $28 million for the
same period one year ago. The decrease was primarily due to a lower gross profit when compared to the same period
one year ago, offset by higher restructuring costs.
- Gross profit rate of 59.9% for the three months ended September 27, 2025 compared to 60.8% for the same period
one year ago. See the gross profit discussion on page 21 for additional details.
- The $5 million year-over-year reduction in the Company’s operating expenses was due to lower sales and marketing
expenses, general and administrative expenses, and research and development expenses, partially offset by higher
restructuring costs.
- Net loss for the three months ended September 27, 2025 was $40 million, compared with $3 million for the same
period one year ago. Net loss per diluted share was $1.73, compared with $0.14 for the same period one year ago.
- The Company’s adjusted return on invested capital (Adjusted ROIC) was (2.0)% on a trailing twelve-month basis for
the period ended September 27, 2025, compared with 4.5% for the comparable period one year ago.
- The Company used $5 million in cash from operating activities for the nine months ended September 27, 2025,
compared with cash provided of $51 million for the same period one year ago.
- Free cash flow used $17 million for the nine months ended September 27, 2025, compared with providing $34 million
for the same period one year ago.
- As of September 27, 2025, the Company had $580 million of borrowings under its credit facility.
19 | 3Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION
The following table sets forth the Company’s results of operations expressed as dollars and percentages of net sales.
Figures are in millions, except percentages and per share amounts. Amounts may not add due to rounding differences.
| Three Months Ended September 27, 2025 | September 28, 2024 | Nine Months Ended September 27, 2025 | September 28, 2024 | |||||
|---|---|---|---|---|---|---|---|---|
| Net sales | $342.9 | 100.0% | $426.6 | 100.0% | $1,064.1 | 100.0% | $1,305.5 | 100.0% |
| Cost of sales | 137.5 | 40.1% | 167.1 | 39.2% | 424.4 | 39.9% | 528.3 | 40.5% |
| Gross profit | 205.4 | 59.9% | 259.5 | 60.8% | 639.7 | 60.1% | 777.2 | 59.5% |
| Operating expenses: | ||||||||
| Sales and marketing | 167.4 | 48.8% | 205.5 | 48.2% | 503.0 | 47.3% | 596.4 | 45.7% |
| General and administrative | 31.8 | 9.3% | 33.1 | 7.8% | 100.0 | 9.4% | 111.7 | 8.6% |
| Research and development | 7.3 | 2.1% | 10.6 | 2.5% | 27.7 | 2.6% | 34.6 | 2.7% |
| Restructuring costs | 39.2 | 11.4% | 2.0 | 0.5% | 47.5 | 4.5% | 14.4 | 1.1% |
| Total operating expenses | 245.7 | 71.7% | 251.1 | 58.9% | 678.2 | 63.7% | 757.1 | 58.0% |
| Operating (loss) income | (40.3) | (11.8%) | 8.4 | 2.0% | (38.5) | (3.6%) | 20.1 | 1.5% |
| Interest expense, net | 12.7 | 3.7% | 12.1 | 2.8% | 35.5 | 3.3% | 36.6 | 2.8% |
| Loss before income taxes | (53.0) | (15.5%) | (3.6) | (0.8%) | (74.0) | (7.0%) | (16.5) | (1.3%) |
| Income tax benefit | (13.2) | (3.9%) | (0.5) | (0.1%) | (0.6) | (0.1%) | (0.9) | (0.1%) |
| Net loss | $(39.8) | (11.6%) | $(3.1) | (0.7%) | $(73.4) | (6.9%) | $(15.7) | (1.2%) |
| Net loss per share: | ||||||||
| Basic | $(1.73) | $(0.14) | $(3.21) | $(0.69) | ||||
| Diluted | $(1.73) | $(0.14) | $(3.21) | $(0.69) | ||||
| Weighted-average number of common shares: | ||||||||
| Basic | 23.0 | 22.6 | 22.9 | 22.6 | ||||
| Diluted | 23.0 | 22.6 | 22.9 | 22.6 |
The percentage of total net sales, by dollar volume, was as follows:
| Three Months Ended September 27, 2025 | September 28, 2024 | Nine Months Ended September 27, 2025 | September 28, 2024 | |
|---|---|---|---|---|
| Retail stores | 87.8% | 87.8% | 87.7% | 87.9% |
| Online, phone, chat and other | 12.2% | 12.2% | 12.3% | 12.1% |
| Total Company | 100.0% | 100.0% | 100.0% | 100.0% |
20 | 3Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION
The components of total net sales change, including comparable net sales changes, were as follows:
| Sales change rates: | Three Months Ended September 27, 2025 | September 28, 2024 | Nine Months Ended September 27, 2025 | September 28, 2024 |
|---|---|---|---|---|
| Retail comparable-store sales (1) | (19%) | (7%) | (17%) | (9%) |
| Online, phone and chat | (20%) | (18%) | (17%) | (17%) |
| Total Retail comparable sales change (1) | (19%) | (9%) | (17%) | (10%) |
| Net opened/closed stores and other | (1%) | (1%) | (1%) | 0% |
| Total Company | (20%) | (10%) | (18%) | (10%) |
(1) Stores are included in the comparable-store calculations in the 13th full month of operations. Stores that have been remodeled or repositioned within
the same shopping center remain in the comparable-store base.
Other sales metrics were as follows:
| Three Months Ended September 27, 2025 | September 28, 2024 | Nine Months Ended September 27, 2025 | September 28, 2024 | |
|---|---|---|---|---|
| Average sales per store (1) (in thousands) | $2,276 | $2,670 | ||
| Average sales per square foot (1) | $735 | $863 | ||
| Stores > $2 million in net sales (2) | 42% | 60% | ||
| Stores > $3 million in net sales (2) | 10% | 20% | ||
| Average revenue per smart bed unit – Total Retail (3) | $5,995 | $5,771 | $5,958 | $5,778 |
(1) Trailing-twelve months Total Retail comparable sales per store open at least one year.
(2) Trailing-twelve months for stores open at least one year (excludes online, phone and chat sales).
(3) Represents Total Retail net sales divided by Total Retail smart bed units.
The number of retail stores operating was as follows:
| Three Months Ended September 27, 2025 | September 28, 2024 | Nine Months Ended September 27, 2025 | September 28, 2024 | |
|---|---|---|---|---|
| Beginning of period | 630 | 646 | 640 | 672 |
| Opened | 2 | 1 | 5 | 11 |
| Closed | (21) | (4) | (34) | (40) |
| End of period | 611 | 643 | 611 | 643 |
21 | 3Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION
Comparison of Three Months Ended September 27, 2025 with Three Months Ended September 28, 2024
Net sales
Net sales for the three months ended September 27, 2025 of $343 million decreased 20% from $427 million for the same
period one year ago driven by lower volume and reduced store count. The net sales change consisted primarily of a 19%
Total Retail comparable sales decrease.
The $84 million net sales decrease compared with the same period one year ago was comprised of the following: (i) a
$69 million decrease in Retail comparable net sales; (ii) a $10 million decrease from online, phone and chat; and (iii) a
$5 million decrease from net store closings and other. Total Retail smart bed unit sales decreased 23% compared with the
prior year. Total Retail average revenue per smart bed unit increased by 4% to $5,995, compared with $5,771 in the prior-
year period.
Gross profit
Gross profit of $205 million for the three months ended September 27, 2025 decreased by $54 million, or 21%, compared
with $260 million for the same period one year ago. The gross profit rate totaled 59.9% of net sales for the three months
ended September 27, 2025, compared to 60.8% in the prior-year comparable period.
The current-year gross profit rate decrease of 0.9 ppt was affected by the following items: (i) higher manufacturing costs
driven primarily by unit deleverage decreased the rate by 1.4 ppt; (ii) unfavorable logistic and home delivery costs due to
lower unit volume decreased the rate by 0.5 ppt; partially offset by (iii) favorable product mix increased the rate by 0.7 ppt;
and (iv) lower promotional activity increased the rate by 0.3 ppt.
Sales and marketing expenses
Sales and marketing expenses for the three months ended September 27, 2025 were $167 million, or 48.8% of net sales,
compared with $205 million, or 48.2% of net sales, for the same period one year ago. The current-year sales and
marketing expenses rate increase of 0.6 ppt. was primarily due to the deleveraging impact of an 20% net sales decline,
partially offset by a 19% decrease in sales and marketing expenses including a 32% lower media spend.
General and administrative expenses
General and administrative (G&A) expenses totaled $32 million, or 9.3% of net sales, for the three months ended
September 27, 2025, compared with $33 million, or 7.8% of net sales, in the prior-year period. The changes in G&A
expenses consisted mainly of: (i) a $1.5 million decrease in stock-based compensation; and (ii) a $1.3 million decrease in
depreciation and amortization; offset by (iii) a $1.1 increase in company-wide, performance-based incentive compensation
due to an adjustment recorded during the prior year period, and (iv) a $0.7 million increase in professional and consulting
fees. The G&A expenses rate decreased by 1.5 ppt. in the current-year period, compared with the same period one year
ago due to the items discussed above offset by the deleveraging impact of lower net sales.
Research and development expenses
Research and development (R&D) expenses totaled $7 million for the three months ended September 27, 2025,
compared with $11 million with the same period one year ago. The changes in R&D expenses were primarily due to lower
headcount and outside services. Moving forward, the Company’s innovation agenda will focus on maintaining and
improving the Company’s core technologies and introducing additional advancements, while driving costs out of the
product.
Interest expense, net
Interest expense, net totaled $13 million for the three months ended September 27, 2025, compared to $12 million for the
same period one year ago. The increase was due to an increase in the average debt outstanding compared to the same
period one year ago offset slightly by a lower weighted-average interest rate.
22 | 3Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION
Restructuring Costs
Restructuring costs for the three months ended September 27, 2025 were $39 million, compared with $2 million for the
same period one year ago. Charges incurred related to this initiative were comprised of contract termination costs,
severance and employee-related benefits, professional fees and other, and asset impairment charges and are included in
the restructuring costs line in the Company’s condensed consolidated statement of operations. The Company expects an
additional $3 million of restructuring costs to be incurred through the remainder of 2025, primarily due to severance and
employee-related benefits, contract termination costs, and asset impairment charges. See Note 12, Restructuring Costs,
of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1, Financial Information, of this
Quarterly Report on Form 10-Q for further information on restructuring costs.
Income tax benefit
Income tax benefit was $13.2 million for the three months ended September 27, 2025, compared with $0.5 million for the
same period one year ago. The change in income tax benefit was primarily due to the impact of the loss before income tax
levels.
The Company evaluates its deferred income taxes on a quarterly basis to determine if valuation allowances are required.
As part of this evaluation, the Company assess whether valuation allowances should be established for any deferred tax
assets that are not considered more likely than not to be realized, using all available evidence, both positive and negative.
This assessment considers, among other matters, the nature, frequency, and severity of historical losses, forecasts of
future profitability, taxable income in available carryback periods and tax planning strategies. In making such judgments,
significant weight is given to evidence that can be objectively verified. The Company did not record any additional
valuation allowance during the three months ended September 27, 2025. The Company continues to assess the need for
the valuation allowance and will make adjustments when appropriate.
Comparison of Nine Months Ended September 27, 2025 with Nine Months Ended September 28, 2024
Net sales
Net sales for the nine months ended September 27, 2025 decreased by $241 million, or 18%, to $1.1 billion, compared
with $1.3 billion for the same period one year ago driven by lower volume and reduced store count.
The net sales decrease consisted primarily of a 17% comparable sales decrease in Total Retail. For additional details, see
the components of total net sales change on page 20.
The $241 million net sales decrease compared with the same period one year ago was comprised of the following: (i) a
$193 million decrease in Retail comparable net sales; (ii) a $27 million decrease in online, phone and other sales; and (iii)
a $21 million decrease resulting from net store closings. Total smart bed unit sales declined 21% compared with the same
period one year ago. Average revenue per smart bed unit in Total Retail increased by 3% to $5,958, compared with
$5,778 in the prior-year period.
Gross profit
Gross profit of $640 million for the nine months ended September 27, 2025 decreased by $137 million, or 18%, compared
with $777 million for the same period one year ago. The gross profit rate increased to 60.1% of net sales for the nine
months ended September 27, 2025, compared to 59.5% in the prior-year comparable period.
The current-year gross profit rate increase of 0.6 ppt was affected by the following items: (i) favorable product mix
increased the rate by 0.8 ppt; (ii) strategic pricing actions partially offset by increased promotional activity increased the
rate by 0.2 ppt; (iii) year-over-year product cost reductions through value engineering and ongoing supplier negotiations
increased the rate by 0.1 ppt; partially offset by (iv) logistic and home delivery costs decreased the rate by 0.5 ppt.
Sales and marketing expenses
Sales and marketing expenses for the nine months ended September 27, 2025 were $503 million, or 47.3% of net sales,
compared with $596 million, or 45.7% of net sales, for the same period one year ago. The current-year sales and
marketing expenses rate increase of 1.6 ppt. was primarily due to deleveraging impact of an 18% net sales decline offset
by a 16% decrease in expenses including 19% lower media spend.
23 | 3Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION
General and administrative expenses
G&A expenses for the nine months ended September 27, 2025 totaled $100 million, or 9.4% of net sales, compared
with $112 million, or 8.6% of net sales, in the prior-year period. The $12 million decrease in G&A expenses consisted of:
(i) a $6.3 million year-over-year decrease in company-wide, performance-based incentive compensation and (ii) a $3.3
million decrease in depreciation and amortization; (iii) a $3.0 million decrease in employee compensation and (iv) a $0.3
million decrease in occupancy expenses; offset by a (v) a $1.3 million increase in professional and consulting fees
primarily related to proxy contest and CEO search costs that occurred during the first quarter of 2025. The G&A expenses
rate increased by 0.8 ppt. in the current-year period, compared with the same period one year ago due to the
deleveraging impact of the 18% net sales decrease.
Research and development expenses
R&D expenses decreased by 20% to $28 million for the nine months ended September 27, 2025, compared with $35
million for the same period one year ago on lower outside services and headcount. While the Company’s consumer
innovation pipeline remains robust, it is re-prioritizing R&D resources in this highly constrained environment. Moving
forward, the Company’s innovation agenda will focus on maintaining and improving the Company’s core technologies and
introducing additional advancements, while driving costs out of the product.
Interest expense, net
Interest expense, net decreased to $36 million for the nine months ended September 27, 2025, compared with $37 million
for the same period one year ago. The $1 million decrease was primarily driven by a lower weighted-average interest rate
compared with the same period one year ago.
Restructuring costs
Restructuring costs for the nine months ended September 27, 2025 were $48 million, compared with $14 million for the
same period one year ago. Charges incurred related to this initiative were comprised of contract termination costs,
severance and employee-related benefits, professional fees and other, and asset impairment charges and are included in
the restructuring costs line in the Company’s condensed consolidated statement of operations. The Company expects an
additional $3 million of restructuring costs to be incurred through the remainder of 2025, primarily due to severance and
employee-related benefits, contract termination costs, and asset impairment charges. See Note 12, Restructuring Costs,
of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1, Financial Information, of this
Quarterly Report on Form 10-Q for further information on restructuring costs.
Income tax benefit
Income tax benefit totaled $0.6 million for the nine months ended September 27, 2025, compared with $0.9 million for the
same period one year ago.
The Company evaluates its deferred income taxes on a quarterly basis to determine if valuation allowances are required.
As part of this evaluation, the Company assess whether valuation allowances should be established for any deferred tax
assets that are not considered more likely than not to be realized, using all available evidence, both positive and negative.
This assessment considers, among other matters, the nature, frequency, and severity of historical losses, forecasts of
future profitability, taxable income in available carryback periods and tax planning strategies. In making such judgments,
significant weight is given to evidence that can be objectively verified. A valuation allowance of $14 million that was
recorded during the nine months ended September 27, 2025. The valuation allowance primarily related to deferred tax
assets on interest expense that are more likely than not to not be realized. The Company continues to assess the need for
the valuation allowance and will make adjustments when appropriate.
24 | 3Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION
Liquidity and Capital Resources
Managing liquidity and capital resources is an important part of the Company’s commitment to deliver superior
shareholder value over time.
The Company’s primary sources of liquidity are cash flows provided by operating activities and cash available under its
revolving credit facility, as amended. As of September 27, 2025, the Company does not have any off-balance sheet
financing other than its $9 million in outstanding letters of credit. The cash generated from ongoing operations and cash
available under the revolving credit facility are expected to be adequate to maintain operations, and fund anticipated
expansion, strategic initiatives and contractual obligations such as lease payments and capital commitments for new retail
stores for the foreseeable future.
Cash and cash equivalents totaled $1.3 million and $2.0 million at September 27, 2025 and December 28, 2024,
respectively. Significant changes in cash and cash equivalents during the nine months ended September 27, 2025
primarily consisted of $5 million of cash used in operating activities, $15 million of cash used in investing activities, and
$20 million of cash provided by financing activities.
The following table summarizes cash flows (in millions). Amounts may not add due to rounding differences:
| Total cash (used in) provided by: | Nine Months Ended September 27, 2025 | September 28, 2024 |
|---|---|---|
| Operating activities | $(5.2) | $50.8 |
| Investing activities | (15.2) | (20.0) |
| Financing activities | 19.6 | (31.8) |
| Net decrease in cash and cash equivalents | $(0.7) | $(0.9) |
Net cash used in operating activities for the nine months ended September 27, 2025 was $5 million, compared with net
cash provided by operating activities of $51 million for the nine months ended September 28, 2024. Significant
components of the year-over-year change in cash provided by operating activities included: (i) a $58 million year-over-
year increase in net loss; (ii) a $20 million fluctuation in income taxes, and (iii) a $13 million fluctuation in the amount of
compensation and benefits accrued and timing of the related payments resulting from year-over-year changes in
Company-wide performance-based incentive compensation; offset by (iv) a $33 million fluctuation in the impairment of
lease and store related assets and strategic investment assets, (v) a $16 million fluctuation in deferred income taxes, and
(vi) a $11 million fluctuation in prepaid expenses.
Net cash used in investing activities for the nine months ended September 27, 2025 was $15 million, compared with
$20 million for the nine months ended September 28, 2024. Cash used to purchase property and equipment was
$12 million for the nine months ended September 27, 2025, compared with $17 million for the same period one year ago.
In addition, the Company used $3 million cash for payment to secure contractual rights during the nine months ended
September 28, 2024.
Net cash provided by financing activities was $20 million for the nine months ended September 27, 2025, compared with
net cash used in financing activities of $32 million for the same period one year ago. Short-term borrowings increased by
$22 million during the current-year period due to an $33 million increase in borrowings under the revolving credit facility to
$580 million and a $11 million decrease in book overdrafts, which are included in the net change in short-term borrowings.
During the nine months ended September 27, 2025, the Company used $2 million of cash for debt issuance costs related
to the credit facility amendment during the first quarter of 2025. During both the nine months ended September 27, 2025
and September 28, 2024, the Company repurchased $1 million of its stock in connection with the vesting of employee
restricted stock awards.
In the second quarter of fiscal 2022, the Company suspended share repurchases under its Board-approved share
repurchase program. At September 27, 2025, there was $348 million remaining authorization under the Board-approved
$600 million share repurchase program. There is no expiration date governing the period over which the Company can
repurchase shares. The Company made no share repurchases under its Board-approved share repurchase program in
either period.
25 | 3Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION
At September 27, 2025, the Company had an aggregate amount of $580 million of borrowings outstanding under its credit
agreement, including $185 million in outstanding term loans and $395 million outstanding under its revolving credit facility,
along with $9 million in outstanding letters of credit. Availability under the revolving credit facility amounted to $82 million.
On November 4, 2025, the Company amended the Credit Agreement. The amendment, among other things: (a) extends
the maturity date of the Credit Agreement to December 3, 2027; (b) reduces the revolving credit facility from $485 million
to $475 million, which decreases further to $465 million on July 31, 2026; (c) replaces the leverage-based pricing grids
used to determine the Applicable Margin and Applicable Commitment Fee Rate (each as defined in the Credit Agreement)
in favor of (I) with respect to Applicable Margin for Term SOFR Loans, (x) 4.0% until December 31, 2026 and (y) 4.25%
starting January 1, 2027 and continuing thereafter, and (II) with respect to the Applicable Commitment Fee Rate, (x)
0.50% until December 31, 2026 and (y) 0.75% starting January 1, 2027 and continuing thereafter; (d) on each Regularly
Scheduled Payment Date (as defined in the Credit Agreement) occurring on and after March 31, 2027, increases the
amortization of outstanding term loans an additional $1,250,000 (for an aggregate scheduled principal payment of
$3,750,000); (e) terminates the accordion feature; (f) adjusts the permissible maximum Net Leverage Ratio (as defined in
the Credit Agreement) to (I) 5.25 to 1.00 for the quarterly reporting period ended September 27, 2025, (II) 4.50 to 1.00 for
the quarterly reporting period ending January 3, 2026, (III) 4.75 to 1.00 for the quarterly reporting period ending April 4,
2026, (IV) 4.80 to 1.00 for the quarterly reporting period ending July 4, 2026, and (V) 4.00 to 1.00 for each quarterly
reporting period thereafter; (g) adjusts the Liquidity financial covenant so that the Company must ensure that liquidity is no
lower than $30 million until September 30, 2026, and $40 million for each monthly reporting period thereafter; (h) adjusts
the permissible minimum Interest Coverage Ratio to (I) 1.50 to 1.00 for the quarterly reporting period ended September
27, 2025, (II) 2.10 to 1.00 for the quarterly reporting periods ending January 3, 2026 and April 4, 2026, (III) 1.80 to 1.00 for
the quarterly reporting period ending July 4, 2026, (IV) 2.10 to 1.00 for the reporting period ending October 3, 2026, and
(V) 2.20 to 1.00 for each quarterly reporting period occurring thereafter; (i) adds a new quarterly minimum EBITDA
covenant test that begins for the quarterly reporting period ending April 4, 2026; (j) adjusts the consolidated EBITDA
calculation to include an addback for certain expenses and costs incurred for the trailing twelve months for discontinued
operations, downsized functions and employment expenses for laid-off employees; and (k) provides for additional and
more frequent reporting requirements. Following such amendment, the Company was in compliance with all covenants.
In connection with the amendment, the Company also agreed to pay the lenders certain amendment fees and to
reimburse the lenders for certain expenses.
Over the past year, due to the conditions affecting our industry and business and our financial condition and results of
operations, we have had to seek waivers and amendments to our credit agreement as we otherwise would not have been
in compliance with the covenants thereunder. While we have received such waivers and amendments in the past, if our
business does not perform as expected, we will require additional waivers or amendments to the Credit Agreement and, if
such waivers or amendments cannot be obtained on commercially reasonable terms or at all, we will be required to seek
alternative financing options, which may not be available at all or available only at significant cost and which may contain
covenants that are more restrictive than those contained in the Credit Agreement. Our inability to obtain any required
waivers or amendments or obtain alternative financing on commercially reasonable terms, if at all, could have a material
adverse impact on our business, results of operations, financial condition and prospects.
Non-GAAP Data Reconciliations
Earnings before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA)
The Company defines earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA) as net loss plus:
income tax expense (or minus income tax benefit), interest expense, depreciation and amortization, stock-based
compensation, restructuring costs, other non-recurring items and asset impairments. Management believes Adjusted
EBITDA is a useful indicator of the Company’s financial performance and its ability to generate cash from operating
activities. The Company’s definition of Adjusted EBITDA may not be comparable to similarly titled definitions used by other
companies. The table below reconciles Adjusted EBITDA, which is a non-GAAP financial measure, to the comparable
GAAP financial measure.
26 | 3Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION
Adjusted EBITDA calculations are as follows (in thousands):
| Three Months Ended September 27, 2025 | September 28, 2024 | Trailing-Twelve Months Ended September 27, 2025 | September 28, 2024 | |
|---|---|---|---|---|
| Net loss | $(39,790) | $(3,136) | $(78,113) | $(40,857) |
| Income tax benefit | (13,212) | (489) | (4,893) | (7,966) |
| Interest expense | 12,687 | 12,057 | 47,244 | 49,313 |
| Depreciation and amortization | 12,975 | 15,859 | 56,706 | 67,335 |
| Stock-based compensation | (788) | 1,432 | 6,615 | 13,523 |
| Restructuring costs (1) | 39,154 | 1,963 | 51,230 | 30,110 |
| Other non-recurring items (2) | 2,228 | — | 5,053 | — |
| Asset impairments | — | — | 1,220 | 198 |
| Adjusted EBITDA | $13,254 | $27,686 | $85,062 | $111,656 |
(1) Represents costs related to business restructuring actions.
(2) Represents costs related to CEO transition activities and proxy contest costs of $0.4 million and $0, respectively, for the three months ended
September 27, 2025 and $1.4 million and $1.9 million, respectively, for the trailing twelve months ended September 27, 2025. These costs were both
initiated in the fourth quarter of fiscal 2024. In addition, represents CFO search costs of $0.2 million and write off of debt issuance cost of $1.6 million
for both the three and trailing twelve months ended September 27, 2025. These costs were both initiated in the third quarter of 2025.
Free Cash Flow
The Company’s “free cash flow” data is considered a non-GAAP financial measure and is not in accordance with, or
preferable to, “net cash provided by operating activities,” or GAAP financial data. However, the Company is providing this
information as it believes it facilitates analysis for investors and financial analysts.
The following table summarizes free cash flow calculations (in thousands):
| Nine Months Ended September 27, 2025 | September 28, 2024 | Trailing-Twelve Months Ended September 27, 2025 | September 28, 2024 | |
|---|---|---|---|---|
| Net cash (used in) provided by operating activities | $(5,159) | $50,824 | $(28,840) | $9,980 |
| Subtract: Purchases of property and equipment | 11,888 | 17,218 | 18,175 | 26,252 |
| Free cash flow | $(17,047) | $33,606 | $(47,015) | $(16,272) |
Non-GAAP Data Reconciliations (continued)
Return on Invested Capital (Adjusted ROIC)
Adjusted ROIC is a financial measure the Company uses to determine how efficiently it deploys its capital. It quantifies the
return the Company earns on its adjusted invested capital. Management believes Adjusted ROIC is also a useful metric
for investors and financial analysts. The Company computes Adjusted ROIC as outlined below. Its definition and
calculation of Adjusted ROIC may not be comparable to similarly titled definitions and calculations used by other
companies.
27 | 3Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION
The tables below reconcile adjusted net operating profit after taxes (Adjusted NOPAT) and total adjusted invested capital,
which are non-GAAP financial measures, to the comparable GAAP financial measures (in thousands):
| Adjusted net operating profit after taxes (Adjusted NOPAT) | Trailing-Twelve Months Ended September 27, 2025 | September 28, 2024 |
|---|---|---|
| Operating income | $(35,762) | $490 |
| Add: Operating lease expense (1) | 24,956 | 27,371 |
| Less: Income taxes (2) | 1,443 | (5,474) |
| Adjusted NOPAT | $(9,363) | $22,387 |
| Average adjusted invested capital | ||
| Total deficit | $(521,342) | $(448,784) |
| Add: Long-term debt (3) | 579,680 | 516,761 |
| Add: Operating lease obligations (4) | 361,029 | 401,153 |
| Total adjusted invested capital at end of period | $419,367 | $469,130 |
| Average adjusted invested capital (5) | $460,891 | $502,494 |
| Adjusted return on invested capital (Adjusted ROIC) (6) | (2.0%) | 4.5% |
(1) Represents the interest expense component of lease expense included in the Company’s financial statements under ASC 842, Leases.
(2) Reflects annual effective income tax rates, before discrete adjustments, of 13.4% and 19.6% for September 27, 2025 and September 28, 2024,
respectively.
(3) Long-term debt includes existing finance lease liabilities.
(4) Reflects operating lease liabilities included in the Company’s financial statements under ASC 842.
(5) Average adjusted invested capital represents the average of the last five fiscal quarters’ ending adjusted invested capital balances.
(6) Adjusted ROIC equals Adjusted NOPAT divided by average adjusted invested capital.
Note - the Company’s adjusted ROIC calculation and data are considered non-GAAP financial measures and are not in accordance with, or preferable
to, GAAP financial data. However, the Company is providing this information as it believes it facilitates analysis of the Company's financial performance
by investors and financial analysts.
GAAP - generally accepted accounting principles in the U.S.
Critical Accounting Policies
The Company discusses its critical accounting policies and estimates in Management’s Discussion and Analysis of
Financial Condition and Results of Operations in the Company’s Annual Report on Form 10-K for the fiscal year ended
December 28, 2024. There were no significant changes in the Company’s critical accounting policies since the end of
fiscal 2024.
28 | 3Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION
Market risk
As filed, 479 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company is exposed to changes in market-based short-term interest rates that will impact net interest expense. If
overall interest rates were one percentage point higher than current rates, annual net income would decrease by
$5.0 million based on the $580 million of borrowings under the credit facility at September 27, 2025. The Company does
not manage the interest-rate volatility risk of borrowings under the credit facility through the use of derivative instruments.
Controls and procedures
As filed, 1,661 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures
The Company maintains disclosure controls and procedures, as defined in Exchange Act Rule 13a-15(e), that are
designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under
the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time
periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated
and communicated to the Company’s management, including its principal executive officer and principal financial officer,
or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The
Company’s management, with the participation of its principal executive officer and principal financial officer, evaluated the
effectiveness of the design and operation of the Company’s disclosure controls and procedures as of the end of the period
covered by this quarterly report. Based on this evaluation, its principal executive officer and principal financial officer
concluded that the Company’s disclosure controls and procedures were effective as of the end of the period covered by
this quarterly report.
Changes in Internal Control
There were no changes in the Company’s internal control over financial reporting during the fiscal quarter ended
September 27, 2025, that have materially affected, or are reasonably likely to materially affect, the Company’s internal
control over financial reporting.
29 | 3Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION
Risk factors
As filed, 1,003 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company’s business, financial condition and operating results are subject to a number of risks and uncertainties,
including both those that are specific to the Company’s business and others that affect all businesses operating in a global
environment. Investors should carefully consider the information in this report under the heading, Management’s
Discussion and Analysis of Financial Condition and Results of Operations, and also the information under the heading,
Risk Factors, in the Company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on
Form 10-Q. The risk factors discussed in the Annual Report on Form 10-K and in subsequent Quarterly Reports on Form
10-Q including this Quarterly Report on Form 10-Q do not identify all risks that the Company faces because its business
operations could also be affected by additional risk factors that are not presently known to the Company or that it currently
considers to be immaterial to its operations.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-09-27. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-06-29 to 2025-09-27 | $342.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2024-12-29 to 2025-09-27 | $1.06bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2025-06-29 to 2025-09-27 | $137.5m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2024-12-29 to 2025-09-27 | $424.4m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2025-06-29 to 2025-09-27 | $205.4m | us-gaap:GrossProfit |
| Gross profit | 9 months2024-12-29 to 2025-09-27 | $639.7m | us-gaap:GrossProfit |
| Research and development | 3 months2025-06-29 to 2025-09-27 | $7.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2024-12-29 to 2025-09-27 | $27.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-06-29 to 2025-09-27 | −$40.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-12-29 to 2025-09-27 | −$38.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-06-29 to 2025-09-27 | $12.7m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months2024-12-29 to 2025-09-27 | $35.5m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2025-06-29 to 2025-09-27 | −$13.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2024-12-29 to 2025-09-27 | −$594.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-06-29 to 2025-09-27 | −$39.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months2024-12-29 to 2025-09-27 | −$73.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-06-29 to 2025-09-27 | −$1.73 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2024-12-29 to 2025-09-27 | −$3.21 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-06-29 to 2025-09-27 | −$1.73 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-12-29 to 2025-09-27 | −$3.21 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-06-29 to 2025-09-27 | 22,964,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2024-12-29 to 2025-09-27 | 22,858,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2024-12-29 to 2025-09-27 | −$5.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2024-12-29 to 2025-09-27 | $11.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2024-12-29 to 2025-09-27 | $1.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2025-09-27 | $1.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-09-27 | $169.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-09-27 | $749.4m | us-gaap:Assets |
| Current liabilities | At period end2025-09-27 | $898.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-09-27 | $1.27bn | us-gaap:Liabilities |
| Current portion of debt | At period end2025-09-27 | $579.5m | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2025-09-27 | −$521.3m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2025-09-27 | 22,790,000 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000827187-25-000121. Last ingested by Listed: Oct 24, 2026, 14:57 ET. Listed shows no prices and gives no investment advice.